LumaCare

Press Release

15 January 2007

For Immediate Release

LumaCare® receives FDA PreMarket Notification for the LC-122M Phototherapeutic Light Source

Newport Beach, Ca

The Food and Drug Administration (FDA) issued a Premarket Notification (510K) for LumaCare® LC122M Phototherapeutic Light Source. This FDA Notification permits LumaCare to offer the LC-122M throughout the entire USA. The LC122M is simple non-coherent light source that can be filter and focused to deliver a wide range of frequencies.

LumaCare® is the leading provider of non-coherent Light Sources for Phototherapeutic Applications as well as Photodynamic Therapy (PDT). PDT is a safe and effective treatment for the most common forms of skin cancer and pre-malignant lesions. According to newly issued clinical reports for the recent EADV 2006 Congress in Rhodes, Photodynamic Therapy is as safe and effective as cryosurgery and produces significantly better cosmetic results.

FDA Approval will permit LumaCare to offer the patented LC-122M as a safe, effective, simple, and low cost solution to lasers and LED arrays, costing at a minimum more than $25,000 each! LumaCare's LC122M end-user price is only $7,500.

LumaCare's LC-122M has been CE-MDD approved for several years and is routinely used throughout the EU. LumaCare is recommended for Phototherapeutic applications as well as PDT for treating basal cell carcinoma and pre-malignant lesions such as actinic (solar) keratoses and Bowen's disease. Basal cell carcinoma, the most common skin cancer, is usually not life threatening but can cause extensive tissue destruction if not treated adequately. Actinic or solar keratoses are hard lumps in the skin, effects of sun damage, and are usually harmless but can potentially develop into squamous cell carcinoma. It is impossible to predict which of the very common Solar keratoses lesions will develop into cancer.

LumaCare® light sources are designed especially for Phototherapeutic treatments such as Acne and almost all PDT protocols. LumaCare will be marketed in the USA by The LumaCare Medical Group a division of MBG Technologies Inc.

LumaCare® light sources have the patented unique functionality to meet the activation requirements of all Phototherapeutic applications and PDT drugs. LumaCare® is the one source solution for any Phototherapy application or PDT drug activation. LumaCare® is the leading provider of Phototherapeutic and PDT flexible multi-frequency lights sources.

Only LumaCare with its patent protocol flexible interchangeable Fiber Optic Probes (FOP) can deliver the necessary light frequencies required for almost any Phototherapeutic application or PDT drug activation.

For further information, and contact details:

LumaCare® is an operating unit of MBG Technologies. LumaCare's charter is to design and market simple, safe, reliable, and low cost Light Sources into the Medical market as a viable alternative to complex and capital intensive laser and LED based systems. LumaCare was founded over 10 years ago and the parent company MBG Technologies was founded in 1990.

For additional information, please visit our web sites:

Web sites: www.LumaCare.com,

e-mail: info@LumaCare.com

In the European Union, contact Dr. Jon Exley, Lynton Lasers, at phone: +44 (1477) 5369777.

In the USA, please call the Newport Beach, CA office at 1-949-644-0126.